Glaukos Co. (NYSE:GKOS) CFO Sells $162,396.80 in Stock

Glaukos Co. (NYSE:GKOS) CFO Alex R. Thurman sold 1,520 shares of the stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total value of $162,396.80. Following the completion of the transaction, the chief financial officer now directly owns 53,431 shares of the company’s stock, valued at $5,708,568.04. This trade represents a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Glaukos Price Performance

Shares of NYSE:GKOS opened at $101.97 on Friday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. The company has a market capitalization of $5.77 billion, a PE ratio of -35.53 and a beta of 0.99. The stock has a fifty day moving average of $130.52 and a 200-day moving average of $135.71. Glaukos Co. has a one year low of $88.16 and a one year high of $163.71.

Glaukos (NYSE:GKOS) last announced its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.02). The company had revenue of $105.50 million for the quarter, compared to analysts’ expectations of $100.72 million. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. As a group, equities analysts anticipate that Glaukos Co. will post -1.08 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Stephens raised Glaukos to a “strong-buy” rating in a research note on Monday, December 2nd. Citigroup raised shares of Glaukos from a “neutral” rating to a “buy” rating and raised their target price for the company from $132.00 to $162.00 in a research note on Wednesday, December 11th. Stifel Nicolaus upped their price target on shares of Glaukos from $153.00 to $175.00 and gave the stock a “buy” rating in a research note on Tuesday, December 31st. UBS Group began coverage on shares of Glaukos in a report on Friday, December 6th. They issued a “buy” rating and a $182.00 price objective for the company. Finally, Morgan Stanley cut Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 target price on the stock. in a report on Monday, December 2nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Glaukos has an average rating of “Moderate Buy” and a consensus price target of $163.25.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in GKOS. Wellington Management Group LLP lifted its position in shares of Glaukos by 294.5% in the 3rd quarter. Wellington Management Group LLP now owns 2,183,766 shares of the medical instruments supplier’s stock valued at $284,501,000 after acquiring an additional 1,630,270 shares in the last quarter. William Blair Investment Management LLC purchased a new stake in shares of Glaukos in the fourth quarter valued at $121,390,000. Alliancebernstein L.P. boosted its position in shares of Glaukos by 1,235.4% in the fourth quarter. Alliancebernstein L.P. now owns 816,153 shares of the medical instruments supplier’s stock worth $122,374,000 after buying an additional 755,035 shares during the period. Norges Bank purchased a new position in shares of Glaukos during the fourth quarter valued at $84,490,000. Finally, Charles Schwab Investment Management Inc. raised its position in Glaukos by 47.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 641,761 shares of the medical instruments supplier’s stock valued at $83,609,000 after buying an additional 207,338 shares during the period. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.